Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma Journal Article
| Authors: | Eguchi, T.; Kadota, K.; Chaft, J.; Evans, B.; Kidd, J.; Tan, K. S.; Dycoco, J.; Kolquist, K.; Davis, T.; Hamilton, S. A.; Yager, K.; Jones, J. T.; Travis, W. D.; Jones, D. R.; Hartman, A. R.; Adusumilli, P. S. |
| Article Title: | Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma |
| Abstract: | Purpose: The goals of our study were (a) to validate a molecular expression signature (cell cycle progression [CCP] score and molecular prognostic score [mPS; combination of CCP and pathological stage {IA or IB}]) that identifies stage I lung adenocarcinoma (ADC) patients with a higher risk of cancer-specific death following curative-intent surgical resection, and (b) to determine whether mPS stratifies prognosis within stage I lung ADC histological subtypes. Methods: Formalin-fixed, paraffin-embedded stage I lung ADC tumor samples from 1200 patients were analyzed for 31 proliferation genes by quantitative RT-PCR. Prognostic discrimination of CCP score and mPS was assessed by Cox proportional hazards regression, using 5-year lung cancer-specific mortality as the primary outcome. Results: In multivariable analysis, CCP score was a prognostic marker for 5-year lung cancer-specific mortality (HR=1.6 per interquartile range; 95% CI, 1.14-2.24; P=0.006). In a multivariable model that included mPS instead of CCP, mPS was a significant prognostic marker for 5-year lung cancer-specific mortality (HR=1.77; 95% CI, 1.18-2.66; P=0.006). Five-year lung cancer-specific survival differed between low-risk and high-risk mPS groups (96% vs 81%; P < 0.001). In patients with intermediate-grade lung ADC of acinar and papillary subtypes, high mPS was associated with worse 5-year lung cancer-specific survival (P < 0.001 and 0.015, respectively), compared with low mPS. Conclusion: This study validates CCP score and mPS as independent prognostic markers for lung cancer-specific mortality and provides quantitative risk assessment, independent of known high-risk features, for stage I lung ADC patients treated with surgery alone. |
| Keywords: | overall survival; adjuvant therapy; chemotherapy; ccp score; molecular prognostic score |
| Journal Title: | Oncotarget |
| Volume: | 7 |
| Issue: | 23 |
| ISSN: | 1949-2553 |
| Publisher: | Impact Journals |
| Date Published: | 2016-06-07 |
| Start Page: | 35241 |
| End Page: | 35256 |
| Language: | English |
| DOI: | 10.18632/oncotarget.9129 |
| PROVIDER: | scopus |
| PUBMED: | 27153551 |
| PMCID: | PMC5085225 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work